BMSN. Home Topics Biotech & Healthcare Channe
Post# of 5066
Posted On: 09/12/2013 1:25:58 AM
BMSN. Home Topics Biotech & Healthcare Channels World News Global Life Science Events Corporate Database Market Reports BioPortfolio
Latest "HemaXellerate" News Stories
01:24 EDT 12th September 2013 | BioPortfolio
Home » Latest News » Latest "HemaXellerate" News Stories
Here are the most relevant search results for "HemaXellerate" found in our extensive news archives from over 250 global news sources.
More Information about HemaXellerate on BioPortfolio
In addition to our news stories we have dozens of PubMed Articles about HemaXellerate for you to read. Along with our medical data and news we also list HemaXellerate Clinical Trials, which are updated daily. BioPortfolio also has a large database of HemaXellerate Companies for you to search.
Search News Articles Only by Keyword: Relevance Date
Showing "HemaXellerate" News Articles, all 11
Tuesday 30th July 2013
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 07/31/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on its subsidiary, Regen BioPharma's Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA) covering the HemaXellerate I? stem cell product for treatment of drug refractory aplastic anemia. "We are currently in the second round of d...
Friday 12th July 2013
Aplastic Anemia - Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Aplastic Anemia - Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-06-29. This 37-page report is available in PDF from $2000. Aplastic Anemia - Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Aplastic Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipelin...
Thursday 6th June 2013
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 06/07/13 -- Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments...
Wednesday 3rd April 2013
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
SAN DIEGO, CA -- (Marketwired) -- 04/04/13 -- Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments. Currently, Regen is focused on two core areas: a)The HemaXellerate Program, which is based on treating disorders of blood production; and b) Our cancer...
Sunday 17th March 2013
Regen BioPharma Receives IND # From FDA for HemaXellerate
SAN DIEGO, CA -- (Marketwire) -- 03/18/13 -- Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. As part of the clinical trial approval process, the FDA will issue com...
Tuesday 5th February 2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate ...
Clinical Trial to Evaluate "First in Class" Approach to Bone Marrow Failure Diseases
Monday 4th February 2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia
SAN DIEGO, CA -- (Marketwire) -- 02/05/13 -- Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I? stem cell drug in patients with drug-refractory aplastic anemia. HemaXellerate I? is a patient-spec...
Thursday 24th January 2013
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product / Bio-Matrix Subsidiary's Publication Is Scientific Basis for IND Submission Currently in Preparation
SAN DIEGO, CA -- (Marketwire) -- 01/24/13 -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medica...
Wednesday 23rd January 2013
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
SAN DIEGO, CA -- (Marketwire) -- 01/24/13 -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate? bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content...10-231.pdf. The publication...
Sunday 18th November 2012
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
SAN DIEGO, CA -- (Marketwire) -- 11/19/12 -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate? product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of st...
Wednesday 3rd October 2012
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Announces HemaXellerate™ As First Product in Development
Company seeks to enter $18 billion market for bone marrow stimulating growth factors San Diego, CA (PRWEB) October 03, 2012 Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc. has begun development of HemaXellerate™, its first clinical product. HemaXellerate™ is a cellular drug designed to heal damaged bon...
Home » Latest News » Latest "HemaXellerate" News Stories
Biotech & Healthcare Channels World News Life Science Events Corporate Database Market Reports Categories
Search BioPortfolio:
BMSN.
Latest "HemaXellerate" News Stories
01:24 EDT 12th September 2013 | BioPortfolio
Home » Latest News » Latest "HemaXellerate" News Stories
Here are the most relevant search results for "HemaXellerate" found in our extensive news archives from over 250 global news sources.
More Information about HemaXellerate on BioPortfolio
In addition to our news stories we have dozens of PubMed Articles about HemaXellerate for you to read. Along with our medical data and news we also list HemaXellerate Clinical Trials, which are updated daily. BioPortfolio also has a large database of HemaXellerate Companies for you to search.
Search News Articles Only by Keyword: Relevance Date
Showing "HemaXellerate" News Articles, all 11
Tuesday 30th July 2013
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 07/31/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on its subsidiary, Regen BioPharma's Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA) covering the HemaXellerate I? stem cell product for treatment of drug refractory aplastic anemia. "We are currently in the second round of d...
Friday 12th July 2013
Aplastic Anemia - Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Aplastic Anemia - Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-06-29. This 37-page report is available in PDF from $2000. Aplastic Anemia - Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Aplastic Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipelin...
Thursday 6th June 2013
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 06/07/13 -- Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments...
Wednesday 3rd April 2013
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
SAN DIEGO, CA -- (Marketwired) -- 04/04/13 -- Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments. Currently, Regen is focused on two core areas: a)The HemaXellerate Program, which is based on treating disorders of blood production; and b) Our cancer...
Sunday 17th March 2013
Regen BioPharma Receives IND # From FDA for HemaXellerate
SAN DIEGO, CA -- (Marketwire) -- 03/18/13 -- Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. As part of the clinical trial approval process, the FDA will issue com...
Tuesday 5th February 2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate ...
Clinical Trial to Evaluate "First in Class" Approach to Bone Marrow Failure Diseases
Monday 4th February 2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia
SAN DIEGO, CA -- (Marketwire) -- 02/05/13 -- Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I? stem cell drug in patients with drug-refractory aplastic anemia. HemaXellerate I? is a patient-spec...
Thursday 24th January 2013
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product / Bio-Matrix Subsidiary's Publication Is Scientific Basis for IND Submission Currently in Preparation
SAN DIEGO, CA -- (Marketwire) -- 01/24/13 -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medica...
Wednesday 23rd January 2013
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
SAN DIEGO, CA -- (Marketwire) -- 01/24/13 -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate? bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content...10-231.pdf. The publication...
Sunday 18th November 2012
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
SAN DIEGO, CA -- (Marketwire) -- 11/19/12 -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate? product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of st...
Wednesday 3rd October 2012
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Announces HemaXellerate™ As First Product in Development
Company seeks to enter $18 billion market for bone marrow stimulating growth factors San Diego, CA (PRWEB) October 03, 2012 Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc. has begun development of HemaXellerate™, its first clinical product. HemaXellerate™ is a cellular drug designed to heal damaged bon...
Home » Latest News » Latest "HemaXellerate" News Stories
Biotech & Healthcare Channels World News Life Science Events Corporate Database Market Reports Categories
Search BioPortfolio:
BMSN.
(0)
(0)